The TIME in TNBC is often enriched with tumor-infiltrating lymphocytes, particularly CD8+ T cells, which are a key effector population capable of directly killing tumor cells and are associated with improved response to immunotherapy (10, 11). Here, CD8A is linked to neoplasm.